WALL Street has brainwashed investors into believing that a “buy and hold” strategy is the best way to make money in the markets. But nothing could be further from the truth.

The truth is there are numerous solid investments right now primed and ready to spin off huge windfalls that could put millions in your pocket. In fact, my research has shown that every year, on average, 43 stocks rally 1,000% or higher!

That means there are 43 opportunities every year to turn $1,000 into $10,000 or turn $10,000 into $100,000. In fact, there’s an average of three to four opportunities to grow your money 1,000% every month.

The key is identifying the golden thread … the DNA of these fantastic opportunities. Now, many of these explosive stocks are genuine penny stocks. Illiquid, volatile and flat-out gambles for even the most skilled investors. We don’t want those stocks.

We want to make as much money as possible with as little risk as possible. Which is why I combed through 13,000 hours of real-time market data in search of a common detectable DNA in the stocks that are rock solid and primed to jump 1,000%.

Finding this common DNA has allowed me to create a strategy for pinpointing stocks on the verge of soaring 1,000% or more.

In this report, I will provide five companies that meet my strict criteria for identifying stocks that will soar 1,000% or higher over the coming months and years.

Let’s get started…

Foundation Medicine (Nasdaq: FMI)

I am incredibly excited about this investment. I expect people will be talking about this company decades from now, just as much as they talk about Pfizer in pharmaceuticals.

Foundation Medicine (Nasdaq: FMI) has all the makings of being a mega-sized company … and just like all those companies, anyone prudent enough to be there, on the ground floor, stands to make money hand over fist in the months ahead.

The firm is dedicated to transforming cancer care through the use of molecular information. This is the development of treatment that is informed by a deep understanding of the genomic changes that contribute to each patient’s unique cancer.

By offering a full suite of comprehensive genomic profiling assays, the company aims to identify the molecular alterations in a patient’s cancer and match them with relevant targeted therapies, immunotherapies and clinical trials.

The goal is to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer.

In short, Foundation Medicine is making strides in a new avenue of health care called precision medicine — medicine designed specifically for the individual.
Throughout all of history, medicine has been one-size-fits-all. The medicine you take for a cold is the same medicine I take for a cold. But what if your cold medicine could be specifically formulated for you … designed specifically for your genetic code?

Personally, I’ve never been much of a pill taker. However, 70% of Americans use at least one prescription drug. More than 50% take at least two. The most common drugs are opioids, antidepressants and antibiotics. In 2015, our total spending on prescription drugs was $425 billion.

And that number defines the opportunity for Foundation Medicine.

You see, the thing is that, for many people, taking a prescription drug is like a cruel joke. That’s because when you look at most clinical trials designed to test a drug before it’s approved by the Food & Drug Administration (FDA) for sale to people, you’ll find that the drug often only works in 30% or 40%, or at most 50%, of people.

Most drugs won’t work in just anybody. That means at least half of our drug spending is just junk science that’s there to make pharmaceutical companies rich.

Though, for some people, the drugs do work like they are supposed to. For others, the drugs work a bit, though the side effects make it a complicated decision if you should use it or not.

By taking into account your specific genetic code, doctors are able to tailor medicine to meet your needs.

The fact is, “generic” medicine fails in about 40% of patients. Research has shown that:

- Antidepressants fail to help 38% of patients.
- Asthma medicine fails to help 40% of patients.
- Diabetes medicine fails to help 43% of patients.
- Arthritis medicine fails to help 50% of patients.

And that’s not over-the-counter medicine that I’m talking about. This is prescribed medicine, like the arthritis medicine Rituximab. It costs over $11,000 for a two-dose treatment … and it fails 50% of the time. It boils down to the fact that each person has their own genetic makeup, and therefore needs a genetically designed prescription.

And that’s just the tip of the iceberg. The National Cancer Institute reported that in 2014 approximately 14.5 million people were diagnosed with cancer. That number is expected to hit nearly 19 million by 2024.

Few around the globe have not had their lives touched by cancer, whether you’re a survivor or a friend or relative of someone who has suffered from cancer. Roughly 39.6% of men and women around the globe will be diagnosed with cancer at some point in their lifetime.

In the United States, nearly $125 billion was spent on cancer care in 2010, and this number is forecast to reach $156 billion in 2020.

And more than half of the most common cancers were traced back to specific genetic codes.

Precision medicine is going to save millions of lives. We are already seeing doctors rallying behind this movement, engineering and prescribing medicine based specifically on one’s genes.

In fact, according to the Personalized Medicine Coalition, 73% of new cancer treatment drugs currently in early stages of development are going to be using genetic data in their creation.

The Anderson Cancer Center — one of the world’s most respected centers devoted exclusively to cancer patient care, research, education and prevention — performed a study on patients with end-stage diseases. It found that precision medicine increased the success rate 440%.

And the University of Health Precision Genomics Program did a similar study, and it had an 815% success increase for treating various cancers.

Precision medicine represents the cusp of something truly revolutionary in the health care field, and
Foundation Medicine stands at the forefront of that development, set to be a disruptor of the health care industry.

Imagine if there was a way to figure out if a drug was going to work for you before you started taking it. You take a test, then you're matched up for a drug based on your genes. In other words, you're getting a drug that lines up with the way your body would actually use it, making it certain that it would work for you.

That's what the goal of precision medicine is. And Foundation Medicine sits at the very peak of this incredibly disruptive movement and technology — to deliver medicine that's precisely right for your body.

When this happens, it's going to be a revolution. A revolution that I believe is going to make Foundation Medicine soar. And equally, you could see the shares of many companies, including giants such as Pfizer and Merck, etc., come crashing down.

You see, right now it's as if we're flying blind. We're being asked to take pills based on a one-size-fits-all strategy. Just imagine if you went to clothing store and found that they only sold one size — medium. What you'd find is that the world would be filled with people that were wearing things that were too big or too small for them.

And that's where we are today with medicine.

Obviously, if you were a clothing manufacturer in this crazy world filled with people wearing the wrong-sized clothes and had the ability to make clothes in small, medium, large, extra large, etc., you know you'd be sitting on a gold mine.

Well, Foundation Medicine is that manufacturer ... and it's sitting on a gold mine.

But you don't have to take my word for it. One of the world's leading pharmaceutical companies — that's perhaps seeing the end of one-size-fits-all pharmaceuticals — has bought into Foundation Medicine in a massive way.

Roche Pharmaceuticals is a Swiss mega pharmaceutical company, the world's largest biotechnology company and the world's leading provider of cancer treatments. In 2015, 25 million patients were treated with one of its top 25 selling medicines. The company focuses on treatment in the areas of:
• Oncology.
• Neuroscience.
• Infectious diseases.
• Immunology.
• Hematology.
• Hemophilia.
• Ophthalmology.
• Respiratory.

Some of the company’s most well-known pharmaceuticals include cancer treatment Avastin, osteoporosis drug Boniva, flu treatment Tamiflu and anti-anxiety drug Valium.

But Roche isn’t limited to just its success in the development of effective treatments. The firm has been one of the most astute companies with its ability to anticipate the next big thing in the pharmaceutical world. The company is perpetually ahead of the curve to invest in it.

For example, on February 2, 1990, Roche spent $492 million (about $900 million in today’s money) to buy a 60% stake into Genentech. I was in college at the time of the purchase, but I still remember the press coverage.

Wall Street analysts thought that Roche was crazy to spend that kind of money on an unproven technology, which turned out to be the new science of using drugs made up of things that exist in our body such as enzymes and proteins.

But despite the noise from Wall Street, the investment proved to be a grand slam for Roche. Genentech was not only a scientific and commercial success, but it also proved to be an enormous stock market success.

A big enough success that Roche bought all of Genentech in 2009 for almost $47 billion.

Roche’s Next Target

Roche has looked ahead and has found its newest target for medical innovation — Foundation Medicine. The firm is spending more than $1 billion to buy a 56% stake in Foundation Medicine.

When I was a Wall Street analyst, I met with Roche’s CEOs, and I heard firsthand from them their philosophy — go big when they have a deep conviction that a technology is going to be something that will revolutionize the world.

That’s what Roche did with Genentech in 1990, and that’s what it’s doing now with Foundation Medicine. Roche spent $50 per share for the 15.6 million shares.

Now, Foundation Medicine’s stock initially went down following the Roche deal. That’s because Roche loved Foundation’s technology so much it had to buy a controlling majority stake — over 50% — to ensure that no one else could come in and snatch it.

However, that also meant Roche had to pay a huge premium to get that control, priced as if it were buying 100% of the company.

After the deal passed, Foundation Medicine’s stock went back down to what it was before the deal happened. But since that time, the stock has steadily gone back up. At the time of writing, you can buy shares of Foundation Medicine for $44.

This is still a slight discount to what Roche paid. And not only is it 12% cheaper, we are also investing in the knowledge that one of the world’s greatest pharmaceutical companies has checked out the technology and validated it with a $1 billion investment.
Second, we're buying in when Foundation Medicine's technology and product set are better developed and established.

Finally, Foundation's sales were $61 million at the time Roche made its deal. For the close of 2016, the company's sales came in at $116.9 million. In 2017, Foundation Medicine's sales are expected to be in the range of $135 million to $145 million, based on the company's estimates.

Reducing the Risk

One of the great things about Roche's investment in Foundation Medicine is that it has completely derisked Foundation Medicine for us. That's because the Roche deal gave Foundation Medicine more than $1 billion in cash. The company is not going to be lacking for capital to develop its technology, products and services.

Second, because Foundation Medicine has enough capital, it won't issue shares again to the public to raise money for these kinds of things. That's good if you own Foundation Medicine stock because it means that its stock will remain scarce.

Third, this influx of cash removes any financial risk in the stock ... in other words, there's no chance of Foundation Medicine going bankrupt. And even though this is not financial ... Roche validating the technology before investing means that we're buying into a sure thing. At least as sure as anything that you're ever going to find on Wall Street.

Follow the Insiders

But why now?

Many investors would prefer to wait until Foundation Medicine is more established.

This is where the final part of my three-part system comes into play. My strategy is quite complicated, but to help explain it today, I broke it down into three phases. I'll quickly go over each of them.

The first phase is what I call disruption analysis. I determine if the company is an industry disruptor. To uncover this, I scientifically research a company to see if it is going to change the entire industry the way Netflix changed watching TV, the way Apple changed phones and the way Amazon changed shopping.

Finding disruptors is one of the foundational pillars to grabbing a 1,000% gain.
This could be a new drug, new technology, a new system for doing things, a new medical device … the list is endless.

But it has to disrupt the industry.

And — this is key — I pay close attention to the potential market size for this disruptive company. If the potential market is small, the stock can only climb so much. But if it is a big potential market, the stock can easily climb 1,000%.

When it comes to Foundation Medicine, you can see the company is set to disrupt the industry with the use of its precision medicine approach. What’s more, its approach is wide-reaching, stretching far beyond more effectively treating cancer patients, extending to a variety of illnesses and diseases that are impacting people.

GlobalData reported that in 2014, the top 10 largest pharmaceutical firms raked in more than $429 billion in revenue, so there is ample room for Foundation Medicine to grow.

The second phase is the number-crunching phase. Once I know a company is going to disrupt an industry, I need to make sure it has the potential to go up 1,000%.

I look at a lot of numbers. Some are really basic.

For example, I look for companies with a market cap of $150 million to $2 billion. Sometimes I’ll push this to $3 billion depending on the stock. That’s because they still have a lot of room to go up.

There are dozens of other numbers I look at that are on my radar, but one of the most important is sales growth. I want to find companies that currently have under $3 billion in sales, while growing sales an average of 10% to 20% a year.

At this rate, a company would double its sales within five years … something which — without fail — catapults the stock price.

While Foundation Medicine’s sales are above my usual range, we have the added bonus of Roche’s purchase of shares, which has helped to derisk the stock, making it incredibly attractive for purchase.

And finally, the third phase of my strategy is insider activity. While most people look at what Wall Street is doing and what the media is saying, I just want to know what insiders are up to. After all, nobody understands a company the way a CEO or COO does.

You see, insiders have been doing a kind of insider buying that most of Wall Street doesn’t pay attention to. This is a kind of buying that I track because it helps me time buy signals so that I’m getting into a stock right before it’s about to soar higher.

This special kind of insider buying happens when insiders issue themselves stock options. And when you look at Foundation Medicine, you’ll see that insiders have been issuing themselves stock options hand over fist.

As you can see in the table below, insiders started doing their secret buying in April of 2016. They continued their purchases in June and October.

Now, you should know that in my experience, this is typical behavior by insiders. They tend to buy six to 12 months ahead of a stock rocketing higher.

And the reason we care is because insiders have the ultimate scoop on a company. They potentially know when sales are beginning to pick up or if a big contract is getting signed or renewed.

The key concept is that it pays to follow what the insiders are doing because it’s a giant heads-up to you that insiders believe the stock is at a point from which they can see it rising.

And that’s exactly what they see going on with Foundation Medicine.

The insiders are loaded up, and they’re expecting shares to keep rallying. That’s our cue to get in on the stock now and ride it higher as positive news of Foundation Medicine’s products get announced.

Action to take: Buy the shares of Foundation Medicine (Nasdaq: FMI).
When I first told readers about Foundation Medicine in February of 2017, it was trading at $21.90. The stock has since moved higher than my entry price. However, because I believe that Foundation Medicine could hand early investors gains of 1,000%, it’s still a great buy. That means you can still add it to your portfolio if you’re comfortable paying more than my buy-in price. Just know that your results may vary from mine depending on what you pay for your shares.

---

**Note:** When I first told readers about Foundation Medicine in February of 2017, it was trading at $21.90. The stock has since moved higher than my entry price. However, because I believe that Foundation Medicine could hand early investors gains of 1,000%, it’s still a great buy. That means you can still add it to your portfolio if you’re comfortable paying more than my buy-in price. Just know that your results may vary from mine depending on what you pay for your shares.

---

**Acuray Incorporated (Nasdaq: ARAY)**

A cancer diagnosis feels like the end of the world. I hope that soon, it doesn’t have to be. Our current way of treating cancer is better than it has ever been in the span of human history, and for a good number of people, that’s “good enough.”

But I don’t believe that there is such thing as “good enough” in any field — least of all in medicine. I want to see progress that will improve the world by leaps and bounds.

You see, innovation has always been the cornerstone of my investment approach because a small amount of money put into a stock with the right innovative product has the ability to hand investors a fortune. If the investor spots it early, that is.

By getting in on the ground floor with new and innovative small-cap and high-growth stocks, we have the opportunity to go for the biggest gains. This is much better than being the late-bloomer on an already exploding technology.

By shifting our focus to emerging technologies, we can be sure that we are at the forefront of profits once the company starts heading to their peak. The key is to follow the innovation. And now, innovation has lead me to what I feel is the next big name in precision medicine — **Acuray Incorporated (Nasdaq: ARAY)**.

---

**Emerging Technology, Emerging Hope**

So far, robotic medicine has taken a little bit of time to get off the ground. It’s understandable why people would be hesitant to have a machine take the reins of their surgery away from their trusted surgeon. Of course, their surgeon is still in control and it isn’t like we’re letting the machines take over.
What people need to know is that companies have been pumping millions into their research departments to come up with new and improved instruments that are safer than conventional surgery.

This is where Accuray steps into the fray.

Accuray has designed a range of products that are so precise they can remove cancerous tumors without having to harm any of the healthy surrounding tissue. This is an absolutely imperative capability for patients with very particular needs, such as patients with brain tumors.

I want to see a world where no one has to be told: “No, we can’t operate on that.”

Accuray has a leading product called CyberKnife which allows surgeons to image and remove tumors that are more difficult to reach through traditional means. Diseases like prostate, lung, brain and pancreatic cancers can all be treated without invasive surgery.

I can understand why it’s daunting for patients and doctors alike to trust these machines up front. It’s such a change to the normal treatment paradigm. But as innovations like these save more and more lives, I believe that the number of hospitals carrying this equipment will drastically increase.

Combined with Accuray’s older system called TomoTherapy, which targets tumors that need as much precision as CyberKnife, 50% of all cancer patients would benefit from targeted radiation therapy versus more aggressive chemotherapy.

Looking at a Broader Horizon

My mind isn’t only controlled by numbers. I know that there is a bigger picture out there, and that the purpose of this innovation is to save lives and grant people another chance at their future. I don’t look at despair and see profit. But I also feel that the best way to see this technology grow in popularity, and see it spread hope throughout hospitals worldwide, is to invest in it and promote its success.

The market is reshaping itself, and we want Accuray to find its niche in it. Accuray will benefit greatly as the radiation industry grows. In fact, the radiotherapy market is projected to be worth $9.47 billion by 2022, according to research firm marketsandmarkets.

All of Accuray’s systems are products that majorly disrupt the radiation market. Traditional radiation treatment is horribly imprecise. For example, if you have a tumor on your brain, you’ll receive radiation all over your head, which means you’ll lose your hair.
If the cancer has spread down the base of your head, you’d end up getting radiation on your head and neck. The side effects could include mouth and gum sores, dry mouth, jaw stiffness, vomiting, a serious swelling condition called lymphedema, and even rapid tooth decay.

So Accuray is doing more than putting out life-saving products. It’s a company that has patient comfort at heart and keeps additional risks to a minimum. This is the disruption that we want to see. And this is the disruption that will kick older, more dangerous methods out of the market.

Right now, hospitals are Accuray’s main clients. Over the years, Accuray has become more attractive to these clients because it brought on additional treatment methods. So when Accuray’s sales representatives go out to pitch their products, they have more than just one therapy to offer medical practitioners.

Combined, CyberKnife, TomoTherapy and Accuray’s up and coming radiology therapy service Radixact have all helped to bring Accuray’s sales up. The company recently reported that revenue increased 5% on a year-over-year basis, and that product revenue growth jumped 9%. From past experience I can tell you that a company like Accuray won’t stay cheap for long, not when its technology has the potential to be a major player in the radiation market.

That’s why I’m recommending that we get into this technology a little early, because that’s what’s going to guarantee us the most gains as possible. Most other companies in this field only trade at 1.5 times its sales, but Accuray is trading at 10 to 15 times its sales — a sure sign of high growth potential.

These types of indicators represent what we want to see in GoingUpness — and a stock that’s about to revolutionize its field.

I believe Accuray will completely revolutionize the way that cancer is treated, and for that reason, I want this technology represented in our portfolio.

**Action to take: Buy Accuray Incorporated (Nasdaq: ARAY).**

**Care.com (Nasdaq: CRCM)**

Need a baby sitter?
A dog walker?
A chef?

**Care.com (NYSE: CRCM)** can help.

As the largest online marketplace for finding and managing family care, Care.com is focused on helping families address their particular life cycle of care needs, whether it’s child care, senior care, special needs care or other family care needs such as pet care, tutoring and housekeeping.

To fit everything into our busy lives, more and more people are starting their search for anything online, and having a one-stop shop set up to answer all your questions and take care of all of your needs will help a company quickly rise to the top. Ease and convenience are major deciding factors in our hectic lives, and Care.com offers both.

And when it comes to families, finding good care for children can not only be difficult, but expensive. Child Care Aware of America issued a report that showed the cost for an infant and a 4-year-old child in full-time care in a center was the biggest cost for a family on average.

When I moved from New York to North Carolina, I knew no one. Being a parent, one of the first things I asked others about was if they could recommend a baby sitter. Many parents won’t give you the names of their baby sitters because a good one — one who’s reliable, trustworthy, punctual and diligent — is hard to find. So, they’ll give you the names of their so-so recommendations.

You quickly figure out that these baby sitters are either perennially late or really not up to do much other than sit around and peck on their phones. Others won't show up at all, often without canceling.
And then there’s a nightmare scenario where you Google the person to discover that he or she has a criminal record or other problem.

To make a long story short, this whole setup was simply ripe for someone to build a business that makes it easier to do this.

Care.com offers child-care related services such as:

- Baby sitter or nanny.
- Preschools.
- Day care.
- Lessons/activities.
- Camps.
- Tutors.

But Care.com didn’t stop with just helping you find someone who has experience taking care of children. It also offers experience at the other end of the spectrum — senior care. Care.com’s offered services include:

- Companions.
- Home care.
- Assisted living.
- Transportation.

Care.com has also added pet care options, such as:

- Dog walkers.
- Pet sitters.
- Boarding.
- Grooming.
- Training.
And if you need a little help around the house, Care.com can help you find:

- Housekeepers.
- House sitters.
- Errand runners.
- Event help.

Care.com has definitely found an underserved need in the world, as its reach has grown to include more than 9.6 million global caregivers and 12.4 million global families across 19 countries.

Within the United States alone, there are 8.1 million U.S. caregivers registered with Care.com. As a result, 89% of U.S. zip codes are covered by Care.com’s various caregivers, and there are more than 5,000 caregivers within 10 miles of 95% of the zip codes in America’s top 20 metro areas.

A Familiar Road

But can Care.com really offer astronomical growth opportunities for investors?

Yes, it can, because we’ve already been down this road before with another company.

Uber.

The goal of Uber was simple — to call for transportation with just a push of a button on your smartphone and have it pick you up within five minutes.

The ride-hailing company went from being a startup to a company that’s now valued at $69 billion. Uber found a way to make it easier, cheaper, safer and more convenient to get car transportation anywhere you go. And people flocked to Uber, sending its value sky-high.

Started in 2009 by Travis Kalanick and Garrett Camp, Uber has grown so that it is now in more than 674 cities with more than 1.5 million active drivers. In 2016, the company earned more than $6.5 billion in revenue. It’s still growing.

Its ease and convenience fulfill a basic need, making it a major disruptor of the transportation industry.

Now imagine that you could do something like this for babysitting. Or if you have elderly parents who need assistance. Or if you’re a pet owner going on vacation and want someone to watch your dog or cat.

Care.com offers that same ease and convenience that so many users have found with Uber, and it’s poised to become a true disruptor in the care services industry.

Care.com’s website offers easy access to show if someone is available at a particular time that you need them.

Furthermore, there are reviews of caregivers by people who have used this person’s services. The caregiver’s listing provides references, and credentials are on Care.com’s website — all of which have already been verified.

By having all this information in one place, valuable time has been saved.

In addition, the website allows you to contact the caregiver and set up the service.

And when the appointment is complete, you can pay through the website too, so there’s no need to worry about negotiating how much you should pay them, having exact cash on hand or writing a check.

If you’re a parent, you’ve probably used Care.com and know how useful it is. It’s the go-to website if you need someone because you want to go to a party or concert without your kids. Or maybe you’re just going to be stuck in a last-minute business meeting.
The Network Effect

One of the reasons Care.com is so useful is that it acts like the Uber app or the Amazon website, or even the eBay website. In other words, everything works to help you do what you came there to do as quickly and easily as possible. You get all the information you need to make a decision, and they make it absolutely easy to take action when you have made your decision.

If you examine the three companies I mentioned — Uber, Amazon and eBay — you’ll see what is called a “network effect.” The easiest way to think about the network effect is through a kind of circular logic:

Question: Why do all the drivers sign up to drive for Uber?
Answer: Because all the customers look for a car/driver through Uber.

Question: Why do the customers look for a car/driver through Uber?
Answer: Because all the drivers sign up to driver for Uber.

You can do this same logic question loop for Amazon and eBay and other dominating companies. Everyone goes to buy stuff from Amazon because it sells everything. And everyone goes to sell their stuff on Amazon because everyone goes there to buy stuff.

Network effects are created as a company experiences massive growth while being the dominant player — if not the only player — in a certain field. Word of mouth feeds it, creating the most profitable kind of business model of all — a monopoly.

By monopoly, I mean that effectively the company has no competition. And that in turn means that the business captures the most market share, and also the most valuable part of the market.

Google is a great example of a monopoly. Google controls the market for the search of information on the Internet. And when you look at Google's
financial statements, you’ll realize how great this is for them. Over the last five years, Google has generated an astonishing $120.9 billion in free cash flow, and it’s averaged a net profit of 21.3% over that time.

As you can see, Google is generating gobs of money.

Care.com has the opportunity to take advantage of a similar situation.

If you look at the overall care services market that Care.com participates in, you’ll see that a lot of it is in the informal part of our economy. By that, I mean that it goes through personal connections and where things are arranged ad hoc.

However, the care-based economy is massive. Care.com estimates that we spend $305 billion a year on care for the areas in which it is involved.

Of that right now, between $8 billion and $10 billion is in the bull’s-eye of Care.com’s market, which it’s actively targeting.

In time, you can expect Care.com to address all of this $305 billion market and dominate it the way that Google, Amazon, Uber and eBay dominate their markets.

A Strong Base for Revenue Growth

Care.com has already proved that it has a great business and a great business model.

Revenue is up 1,154% from 2010.

Care.com’s gross profit margins of 80% show you how powerful a business model this is.

Now, Care.com is just on the cusp of becoming profitable on an operating basis, and there’s a good reason for this. You see, companies like Care.com are based on building a technology and operational platform. This platform, for the most part, is a fixed cost.
In other words, there reaches a point where the whole thing is paid for by existing customers. And when the next customer buys, 100% of the amount they spend represents 100% profit. And the same is true for each customer after that, too.

This is the secret to companies such as Google, Microsoft and most Internet and software companies.

And when you combine the impact of being a monopoly with this particular fixed-cost business model, you have a gold mine.

That’s why Microsoft’s stock, even today, is a stock market superstar and why Google continues to be an incredibly good stock to own. I believe that Care.com is positioned to join these companies in generating incredible returns as it dominates the business of providing care to our kids, parents and pets.

**Google’s Big Bet**

Now, you should know that Google appears to understand exactly what I’m telling you. This is why Google plunked down $46.4 million on June 29, 2016 to buy a 17% stake in Care.com.

Remember that Care.com is still in its infancy stage. So, $46.4 million is a big chunk to take of this small company.

And best of all, Care.com’s business is in even better shape than it was when Google bought in. Its sales are higher than in June 2016.

**The Insider Crowd**

You shouldn’t be surprised to hear that Google isn’t the only one taking a big stake in Care.com.

Fitting perfectly into Phase III of my analysis, the management of Care.com has also scooped up a large
chunk of the firm. The management team of Care.com currently owns 12.8 million shares of this stocks, or 35.9% of the company. At its current market cap of $482 million, that's around $168 million in value that's owned by company insiders.

Beyond this huge ownership stake, we can also see that management has issued itself options recently. This is a kind of insider buying that I check for because it gives a clue into the mind-set of the management. A management team that thinks their stock is going to go up will time the issuance of its options to align with their expectations.

And when you look at Care.com, you'll see that management has helped itself to the equivalent of 17,859 shares valued at $289,315.

Now, that doesn't seem like a huge amount, but you need to remember that Care.com is a small company, and it's going to be the owner of a monopoly on coordinating the care of kids, seniors and pets — a $305 billion market.

If Care.com shares soared 10 times from here, these shares would be worth $28.93 million. And that's not a pipe dream.

Google's purchase of Care.com shares shows that expectation are high for the company. And the combination of having an industry monopoly and the most profitable business model says there is a very good chance of Care.com living up — if not exceeding — these expectations. This is why now is an incredible time to buy shares of Care.com.

**Action to take:** Buy the shares of Care.com (NYSE: CRCM).

**Note:** When I first told readers about Care.com in February of 2017, it was trading at $9.34. The stock has since moved higher than my entry price. However, because I believe that Care.com could hand early investors gains of 1,000%, it's still a great buy. That means you can still add it to your portfolio if you're comfortable paying more than my buy-in price. Just know that your results may vary from mine depending on what you pay for your shares.

---

**Iridium Communications (Nasdaq: IRDM)**

It’s no secret that we’re heading into a new era of communication and technology. The first stage of this started with the internet, which served the purpose of bringing millions of people together from all around the globe. This was the “internet of people.”

But now we’re beginning to enter a second stage of growth, and it’s what many people in the markets are calling the “Internet 2.0” — or, the Internet of Things.

You see, with the Internet of Things, the devices we use every day are getting more and more connected. Our cars, homes, even the scanners at our grocery stores are being implanted with more and more sensors and chips to better interact with the world — and one another.

Of course, for these sensors to interact with each other and the computers that run our daily lives, they need to connect with each other first. Those connections are made through the infrastructure set up by global communications companies.

One of these companies is Iridium Communications Inc. (Nasdaq: IRDM), a satellite communication company.

**Taking Stock in Satellites**

If you’ve ever stared up at the night sky and wondered what was up there, I doubt that satellites would be your first thought. After all, they aren't nearly as visible as the bright stars and planets we like to dream about.
Truth is, there are thousands of satellites orbiting our world every minute of every day. These cosmic outposts form the basis for a good portion of our electronic communication.

So, with the Internet of Things rapidly accelerating, it’s almost a no-brainer to get in on the ground floor of this infrastructure.

Iridium is a company that not only owns a number of these satellites, but also performs maintenance on them. So even though it sends satellites into space on a regular basis, it’s also developing new network technologies for more far-reaching communications.

Back in September of 2017, Iridium formed a partnership with Magnitude Space, an emerging small satellite company. The partnership is meant to collaboratively expand both company’s opportunities for space-based Internet of Things services with the development of reliable, Low Power Global Area Network (LPGAN) technologies.

For those unfamiliar with LPGAN, this is essentially a type of wireless communication system set up across a wide area network — so you can imagine how using satellites helps companies get their signals to a greater number of devices.

And as more companies hook their products into the Internet of Things, there will be a growing need for low-power, low-cost monitoring and tracking options — with the goal to bring connectivity to even the most remote locations around the world.

To understand how Iridium fits into this conversation, let’s take a look at how the satellite business works.

**Profits in Orbit**

The nature of the satellite business is that you have to spend a lot of money up front to build out your infrastructure. That’s because it costs a lot of money to build satellites and launch them into space before you can actually start to use them.
However, once the satellites are operational, they start to generate a lot of money. And because Iridium’s revenues are subscription-based, there’s a good chance that a reliable amount of money is going to flow into the company on a regular basis.

The business is also long-term in nature because of a lack of competition for Iridium. This is mostly due to the fact that the costs of putting up satellites is sky-high. Not many companies have the capital or the technical prowess to do it.

Now you see, Iridium is uniquely positioned to become a major network provider for the Internet of Things revolution for a few different reasons:

• Although its market share was only at 12.2% in 2015, they’re ahead of the game in launching satellites into space. So, they’re poised to capture more market share.
• It competes in attractive and growing markets with favorable dynamics and high barriers to entry.
• The key sectors it participates in are land/mobile handsets, machine-to-machine, maritime, aviation and the U.S. Government — all highly-profitable avenues.
• It has a business plan for next-generation satellite constellation called Iridium NEXT.
• Its system of subscription-based revenue means a steady stream of revenue.
• Its number of Internet of Things customers has grown at a rate of 20% per year since 2011. This shows that the service is in demand and will give more reliable profits.
• It benefits from a large and low-cost ecosystem of partners, robust portfolio and large, highly-profitable recurring service revenue base

Set to Launch

As you know, I measure every possible investment up against my GoingUpness system. I want to make sure that, before I suggest we get in on a stock, it has the right markers for success from the get-go.

So, first let’s get into some statistics about Iridium’s ValueAbility. I want to make sure that the company’s product, stock and future holds enough value to make it worthwhile for our investment.

Iridium owns a growing business in a growing market. With its revenues being up for four years straight, it is the market leader in both subscriber base and revenue.

This market growth is no laughing matter, either. The Internet of Things satellite communications market was $3.36 billion in 2015 and is expected to grow at a rate of at least 12% per year. So we want to get into Iridium now, before its stock price begins to reflect its high-growth market potential.

Now, as I told you before, there is a huge upfront cost to the satellite business that might look a bit intimidating to you at first. So what you’re going to see is that Iridium has a high amount of debt — $1.376 billion of it. However, with current interest rates being so low, this is a smart way for Iridium to fund its business.

For investors, this is good thing, because it reduces the amount of stock that’s issued — thus increasing Iridium’s ScarceAbility.

Bottom line: Iridium will benefit greatly from the Internet of Things revolution and will make an everyday change to people’s lives. As a result, I believe that Iridium has the potential to send our portfolio into the stratosphere.

Action to take: Buy Iridium Communications Inc. (Nasdaq: IRDM).

Cogint Inc. (Nasdaq: COGT)

Editor’s Note: I considered a silver-mining play for your fifth position, but it lost its ValueAbility factor
— a critical component of GoingUpness — and I no longer believe it’s set to deliver Extreme Fortunes-worthy gains within a year. It’s on my watch list in case it regains its GoingUpness factor, but in the meantime, I have a new revolutionary recommendation that has the potential to rally 1,000% or higher in the coming months and years.

Cogint Inc. (Nasdaq: COGT) is a data collection company with a mission to transform points of data into intelligence that can be used by small-business owners.

See, you and I are generating “data” all of the time: when we go to the grocery store, when we watch TV, when we apply for a credit card — all of our activities get recorded and stored.

This data is then analyzed and turned into information that companies can use to make their businesses more efficient and to grow their customer base.

Data collection isn’t a new concept; large companies like Facebook and Amazon have been using this information to their advantage for years now, but what makes Cogint unique to its field is the company’s market focus: small-business owners.

This is very important because the average small business (which is defined as a company that has 500 employees or fewer) can’t collect the data that it needs on its own to be competitive. It requires too much scale.

Small businesses don’t make enough money to run their own data farms. And they also aren’t able to go to larger data institutions, like IBM or Oracle, to run these data sets for them, because they don’t make enough money for the big players in the game to waste their time partnering up with them.

That’s where Cogint comes in.

**Helping Out the Little Guys**

Cogint targets all of the small- and medium-sized businesses that the big guys don’t want, and they’re efficient because they don’t try to overextend themselves by reaching outside of their market.

However, Cogint isn’t limited by “small-time” market potential — its current data intelligence market is at a whopping $67 dollars and counting already. But I can tell you that these numbers are going to explode higher and do so rapidly, because data intelligence lies at the heart of the much greater Internet of Things revolution.
Based on the research that I’ve already done in my Profits Unlimited service, I believe that the Internet of Things is going to be the dominant trend for years to come. And Cogint is set up to benefit perfectly from this, as its service relies on the artificial intelligence that generates the data it collects.

So, while Cogint itself may be a small company, it’s playing in a very, very large field. And for that reason, I believe that it has the potential to be a 1,000% winner for our portfolio.

**Massive Market Potential**

The profit potential for Cogint is simply massive.

The best way to determine this is to look at the current market that the company’s sitting in. Now, there’s no way that Cogint would ever be able to target the entire number of employers that make up that market space. That’s just unrealistic.

However, it’s completely in the realm of possibility for Cogint to target 5% of those employers … if not more. So, if Cogint could target even 5% of the current $67 billion data intelligence market, then the company would stand to make $3.3 billion in revenue. Even targeting just 1% of this market equates to $670 million today. That’s huge!

And remember, Cogint can target a much wider audience than larger data collection firms … because there are many more small- and medium-sized businesses than there are Fortune 500 companies.

But when we go to look at the valuation of Cogint, it’s clear that the company is undervalued, as it has a market cap of just $285 million. Wall Street analysts project that Cogint will only increase its sales growth by 26% in 2017, and by only 22% in 2018.

I believe that these estimates are too low. I could see Cogint increasing its sales by 30% to 35% in 2017, and then by at least another 35% in 2018. And this is great news for us because we’ll be able to swoop in and buy shares of the company now while they’re cheap, before other investors start to pay attention to Cogint and bid the stock price up.

After all, insiders are already beginning to pay attention to this company…
Following the Money Trail

Insiders have been eating up shares of Cogint's stock in anticipation of the price going up.

Over the past 12 months, insiders have bought over $2.5 million worth of Cogint’s shares. That’s a lot of money spent on such a small company.

Even better, the buying has been widespread across Cogint’s upper management team, which is a great sign of investor confidence. Cogint’s own COO, Jordan Baker, purchased 40,000 shares of Cogint in March of 2017 alone.

I always look to see if this type of insider buying is taking place because it means that management knows the growth potential of its company. And right now, insiders clearly believe that Cogint will be able to dominate the data collection space for small-business owners.

However, the market isn’t pricing in the amazing opportunity that I believe Cogint will bring investors. That’s why now is the perfect time to get into Cogint Inc. … before big-money investors come in and bid the stock price higher.

Action to take: Buy shares of Cogint Inc. (Nasdaq: COGT).

Note: When I first told readers about Cogint in March of 2017, it was trading at $3.99. The stock has since moved higher than my entry price. However, because I believe that Cogint could hand early investors gains of 1,000%, it’s still a great buy. That means you can still add it to your portfolio if you’re comfortable paying more than my buy-in price. Just know that your results may vary from mine depending on what you pay for your shares.

A Great Start for Extreme Fortunes

These are just five of the 43 stocks that have the potential to rally 1,000% or higher each year.

These companies meet my system of identifying companies that have the three key signs that point to a price explosion:

• Phase 1: Focus on companies that will disrupt the industry.
• Phase 2: Focus on the numbers – specifically sales growth.
• Phase 3: Focus on insider activity.

And with my Extreme Fortunes service, I will continue to uncover great opportunities for my subscribers. To make sure that you can take advantage of all the massive gains that are still coming your way with this system, be sure to read the Extreme Fortunes trading manual.

Regards,

Paul Mampilly
Editor, Extreme Fortunes